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The response of a host animal to primary viral infection is complex, and the 
factors essential for recovery from the infection are difficult to define. Immune 
responses, both cell-mediated and hulnoral, interferon production, pyrexia, and 
local changes in  acidity and oxygen tension in infected tissues have all been 
ascribed possible roles in recovery (1). The importance of any single mechanism 
probably varies  in  diseases  of  different pathogenesis  or  at  particular  times 
during  the  course of infection,  and  there will sometimes be interaction  and 
synergism between individual factors. 
Since neutralizing antibodies and interferon have well documented modes of 
antiviral activity, they could logically be assigned rather more importance than 
cell-mediated immunity, which has no clearly demonstrated  antiviral mech- 
anism.  However, an  increasing body of evidence derived from the  study of 
human  infants  with  primary  immunological  deficiency diseases  points  to  a 
very  important,  perhaps  even  essential  role  for  a  thymus-dependent,  cell- 
mediated  immune  response  in  recovery from  vaccinia  virus  infection  (2). 
Experimental evidence concerning this area of host-virus relations is meager, 
but recently Hirsch et al.  (3)  showed that heterologous anti-thymocyte serum 
(ATS)  1 caused significantly increased mortality and morbidity from intravenous 
vaccinia infection in mice. They postulated that this was due to suppression of 
cell-mediated immunity; however no direct evidence was produced to show that 
the cell-mediated immune response to vaccinia virus was suppressed by ATS. 
This was  assumed on the basis  of an immunosuppressive potency test usiag 
lymphocytic choriomeningitis virus  (4). 
Previously, Allison and Friedman (5,  6) had produced sound evidence that 
the  regression  of  primary  tumours  caused  by fibroma  virus  in  rabbits  was 
dependent upon cell-mediated immunity. However, this and other work con- 
i Abbreviations use~ in this paper: AMS, rabbit anti-mouse macrophage serum; ATS, rabbit 
anti-mouse thymocyte serum; MEM, minimal essential medium; NRS, normal rabbit serum; 
PBS, phosphate-buffered saline; PFU,  virus plaque-forming units;  RBC, red blood cells 
WBC, white blood  cells. 
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cerning  virus-induced tumours  (7)  may  not  illustrate  mechanisms  for  the 
control of cytopathic virus infection. 
The present series  of  investigations was  designed to  elucidate the  relative 
importance of different mechanisms of recovery from a generalized viral infec- 
tion. For reasons outlined below, mousepox was  chosen as  the  experimental 
model. 
Ectromelia virus, a member of the vaccinia subgroup of the poxvirus group, 
is a  natural mouse pathogen; it causes a  generalized disease, mousepox, which 
is  strikingly similar to human exanthems of viral etiology (8).  Virulent and 
avirulent virus strains, and resistant and susceptible mouse strains are available 
(9).  Cell-mediated (delayed hypersensitivity) and humoral immune responses 
(10)  and interferon (11)  are  generated during infection, and  can be  readily. 
quantified. Thus, mousepox provides a  flexible experimental model in which 
mechanisms of recovery from a  generalized viral infection may be studied. It 
has not yet been comprehensively exploited for this specific purpose, although 
it has been the subject of extensive studies which have been reviewed period- 
ically (12-14). 
In this investigation, heterologous anti-thymocyte serum has been used in 
an attempt to clarify the roles of cellular and humoral immunity and interferon 
production in the  process  of recovery from a  primary infection. The results 
suggest an essential role for cell-mediated immunity. 
Materials and Methods 
Animals.--Inbred  C57BL mice and outbred mice of the multicolored Walter and Eliza Hall 
Institute strain (stock mice) were obtained from breeding colonies in this laboratory and used 
when young adults. 
Virus Strain.--Stocks  of virulent Moscow strain ectromelia virus (12) were obtained in the 
form of 0.95% saline suspensions  from supernatants of homogenates of infected mouse livers or 
spleens. Stocks of avirutent Hampstead egg strain ectromelia virus (12) were obtained from 
infected chorioallantoic membranes of 14-day old chick embryos. Genetron extraction of crude 
ectromelia virus stocks was sometimes employed to obtain cleaner virus suspensions (15). 
Semliki Forest virus stock was an homogenate of infected mouse brain in saline. 
Portions of all stocks were stored at -70°C and were always dispersed by an ultrasonic 
probe (Measuring and Scientific  Equipment Ltd., London, England) before use. 
Cell Cultures.--Continuous line mouse fibroblasts (L929) were grown at 37°C in Eagle's 
minimal essential medium (MEM) supplemented with folic acid, tryptose-phosphate  broth, 
dextrose, 10% bovine serum, and antibiotics. 
Plaque Assays.--L929  cells were seeded into 60 mm Petri dishes (Falcon Plastics, Los 
Angeles, Calif.) in 5 ml of a modified medium consisting of MEM with 5% heat-inactivated 
(56°C for 60 rain) bovine serum. Confluent monolayers were infected with virus suspended in 
MEM with 2% fetal calf serum using 0.2 ml per dish for 60 min at 37°C, and then overlaid with 
5 ml modified  medium containing 0.01% DEAE dextran and 0.75% Bacto agar (Difco Labora- 
tories Inc., Detroit, Mich.). Infected cultures were incubated at 35°C. In the case of ectromelia 
virus, an additional 5 ml overlay was added after 3 days, and 4 ml staining overlay (1:10,000 
neutral red) after 5 days. Plaques were counted at 6 or 7 days. For Semliki Forest virus, 2 ml 
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Neutralization Tests.--Mouse  sera were assayed for anti-ectromelia activity by a  plaque 
reduction method. Samples of Moscow strain ectromelia virus to give 50-100  plaque forming 
units (PFU) per L929 monolayer were incubated with serial doubling dilutions of serum in 
MEM with 2% fetal calf serum for 2 hr at 37°C;  each mixture was then assayed for PFU on 
duplicate L929 cultures. Controls included serial doubling dilutions of a known stock antiserum 
and normal mouse serum. The latter was needed because of enhancement of plaquing efficiency 
which occurred at high mouse serum concentrations. The end point was taken as the last dilu- 
tion resulting in 50% reduction of plaque count below the normal mouse serum control. 
Test sera were heat-treated at 56°C for 30 rain to inactivate the free virus present in speci- 
mens from infected mice. This procedure was also found to eliminate nonspecific neutralization 
of virus by the small amounts of heparin in some sera. The addition of excess complement  or the 
degree of purity of virus stocks used did not affect end points, but one stock of genetron-puri- 
fled virus was used throughout. 
Since the ectromelia virus stocks had a high ratio of mouse-infectious  units to PFU (approxi- 
mately 50:1)  it was desirable to ensure that the neutralization of PFU in vitro reflected the 
neutralization of mouse-infectious units. Therefore a  parallel test was set up in  which  two 
samples of the same dilutions of a  stock mouse antiserum (and appropriate normal mouse 
serum controls) were allowed to interact with two different concentrations of virus for 2 hr at 
37°C.  One virus concentration was chosen for the routine plaque reduction test described 
above. The other was chosen so that when unneutralized it contained a minimal 100% lethal 
dose for stock mice (about 10 PFU) when a volume of 0.04 ml was injected subcutaneously into 
the foot. 10 mice were infected for each serum dilution and deaths recorded. All 10 mice in 
control groups died. The neutralization end point in vivo was taken as the last dilution of anti- 
serum at which less than 5 out of 10 mice died. This occurred at a 1:512  dilution, whereas the 
parallel in vitro test gave an end point at 1 : 1024, thus indicating that plaque reduction in vitro 
is a meaningful assay of neutralization of viral infectivity  for the mouse. 
Interferon Assay.--The method used involved plaque reduction of Semliki Forest virus and 
was essentially similar to that of Subrahmanyan and Mires (11) with the exception that L929 
cells were used instead of mouse embryo fibroblasts. 
To ensure that plaque reduction activity against Semliki  Forest virus  reflected  similar 
activity against the virulent Moscow strain of ectromelia virus, two parallel assays were per- 
formed with a standard preparation of interferon, one with each virus. The assays gave inter- 
feron concentrations of 590 units/ml using Semliki Forest virus and 450 units/ml using ectro- 
melia virus. 
Anti-Eetromelia Serum.--C57BL  mice were immunized with two injections of Hampstead 
Egg ectromelia virus 8 wk apart. The first injection (106 PFU) was given subcutaneously into 
the foot and the second (5 X  l0  s PFU) intraperitoneally. All animals were bled 7 days after the 
second injection, the sera pooled, heat-inactivated at 56°C for 30 rain, and stored in portions 
at  -- 20°C. 
Mouse Cell Suspensions.--Thymuses  were removed aseptically, cut into pieces, and pressed 
through stainless steel sieves into MEM. After dissociation of clumps by pipetting, the suspen- 
sions were filtered through cotton-wool columns, washed three times in Puck's A saline, and 
suspended for injection in Puck's A saline containing 10 international units (IU) heparin/ml. 
Viability of the final suspension was assessed by trypan blue (0.05%)  exclusion. It was usually 
greater than 90%. 
Peritoneal cells were obtained by lavage of the unstimulated peritoneal cavity with 4 ml 
Ca- and Mg-free phosphate-buffered  saline (PBS). Red blood cells (RBC) were separated from 
blood obtained from the retro-orbital venous plexus with a Pasteur pipette containing a small 
volume of heparinized saline (10 IU/ml). 
Anti-Thymocyte Serum (A TS).--Antisera to C57BL mouse thymocytes were raised by the 1038  EFFECTS  OF  ANTI--THYIgIOCYTE SERUM  ON  MOUSEPOX 
method of Levey and Medawar '(16). Rabbits were given two intravenous injections of 2  X 
108 and 109 living thymocytes respectively, 14 days apart, and were bled 7 and 9 days after the 
second injection. Sera were pooled, heat-inactivated at 56°C for 30 min, and stored at --70°C. 
This ATS pool was shown to reduce morbidity and mortality in mice infected with lymphocytic 
choriomeningifis virus, an indication of suppression of the cell-mediated immune response (4). 
Anti-Macrophage  Serum  (AMS).--Peritoneal  macrophages were harvested from C57BL 
mice 6 days after the intraperitoneal injection of 3 ml fluid thioglycollate medium (Difco). This 
increased the yield 5- to 10-fold over normal numbers. The cells were washed, suspended in 
MEM with  10% fetal calf serum, and dispensed in 5 ml volumes into 60 mm plastic Petri 
dishes. Mter 24 hr at 37°C  in a  humid 5%  CO2 atmosphere,  macrophage monolayers had 
formed on the plastic; nonadherent cells were washed off with saline and the adherent cells 
removed with a rubber policeman, washed in Puck's A saline,  and  suspended for injection in 
Puck's A saline with 10 IU heparin/ml. This procedure produced an inoculum composed of 
97% very large macrophages, with smaller cells and occasional RBC making up the remaining 
3%. Viability was 70%. Rabbits were given two intravenous injections of  108  macrophages 
14 days apart and bled 7 and 8 days after the second injection. 
Normal rabbit serum (NRS) was obtained from unimmunized animals. Sara were pooled, 
heat-inactivated at 56°C for 30 min, and stored at -- 70°C. 
Agglutination Tests.--A tube agglutination method similar to that described by Mackaness 
and Hill (17) was employed for thymocytes and peritoneal cells. Fractions of washed cell sus- 
pensions in Ca- and Mg-free PBS at a concentration of 2 X  107 per milliliter were mixed with 
equal volumes of serial twofold dilutions of test sera in a final volume of 0.2 ml and let stand at 
2°C in an ice bath. The cells were resuspended once by vigorous shaking after 30 min and exam- 
ined microscopically  for agglutination at 60 min. 
Hemagglutination titers were determined in standard hemispherical well trays using 0.25 
ml volumes of serum dilutions to which were added 0.25  ml of 0.5% v/v washed RBC  in 
PBS. RBC were resuspended after 30 and 60 rain at 37°C and then left overnight at 4°C before 
reading. 
Immunofluorescence Tests.--Binding  of rabbit gamma globulin to mouse thymocytes and 
peritoneal macrophages was detected by an indirect method. 
Washed thymocytes at a concentration of 2 X  10  ~ per milliliter in PBS were incubated at 
37°C for 30 min with dilutions of sera. They were then washed twice with large volumes of 
PBS and finally suspended in a drop of fetal calf serum and smeared on a glass slide.  After 
air-drying  for  60  rain  the  smears  were  fixed  for  10  min  with  acetone,  dried,  and 
stored at --20°C. 
Peritoneal cells from normal, unstimulated mice were suspended in MEM with 10% fetal 
calf serum and placed in small slide-ring culture chambers (18) at less than monolayer density 
and incubated at 37°C for 24 hr in a humidified air atmosphere with 5% CO2. Cultures were 
then washed vigorously over a saline fountain (19) to remove nonadherent cells: this resulted 
in pure, sparse macrophage cultures on the glass slide floor of the chamber, since other cell types 
had been phagocytized or washed away. The macrophages were then incubated for 30 min at 
37°C in MEM containing various concentrations of the rabbit sera to be tested. After vigorous 
washing over the saline fountain the cultures were dried (60 min) and acetone-fixed (10 rain) in 
the intact culture chambers. Acetone was then removed and the slide and ring components of 
the chambers separated, thus leaving the fixed macrophages on a glass slide. These preparations 
were dried and stored at --20°C. 
Thymocytes  and  macrophages  were  stained  at  room  temperature  for  20  min  using 
fluorescein-conjugated goat anti-(rabbit globulin)  globulin (Microbiological  Associates, Inc., 
Bethesda, Md.) with 10% rhodamine bovine albumin as a counterstain. The cells were care- 
fully washed for 20 min with two changes of PBS, dried, and mounted in a mixture of 90% 
glycerol and 10% PBS. They were examined with a fluorescence microscope with camera at- R.  V.  BLANDEN  1039 
tachment and photographed using exposure times of 30 to 60 sec with high speed ektachrome 
film (ASA 160). 
Hematology.--Mice were bled from the retro-orbital plexus with calibrated Pasteur pipettes 
and 0.1 ml of blood from each mouse was diluted with 0.02 ml saline containing 10 IU heparin/ 
ml. Further dilutions were performed with particle-free saline and total RBC were counted in a 
Coulter Counter (Model B, Coulter Electronics, Hialeah, Fla.). 
To obtain total white blood cell (WBC) counts, RBC were first lysed with 0.02% white 
Saponin (British Drug Houses Ltd., Poole, England) in saline.  Differential WBC counts were 
made on 100 WBC in Wright-stained smears. 
Delayed Hypersensitivity in the Footpad.--The  general method  used  has  been  described 
previously  (20).  Approximately  106  PFU  Moscow  ectromelia  virus  contained  in  infected 
spleen homogenate were injected into the right hind footpad in a  volume of 0.04  ml. After 
3,  6,  and  24 hr the thickness of each hind foot was measured to 0.0S  mm with dial gauge 
calipers (Schnelltaster, H. C. KrSplin GmbH, Schluchtern, Hessen, Germany). Since the right 
and left hind feet of the mouse do not differ in size, the difference  between them indicates the 
level of hypersensitivity. Unimmunized controls were always tested simultaneously to deter- 
mine the amount of nonspecific inflammatory swelling due to the test injection. 
Assay  of Virus in Liver, Spleen, Foot, Blood Cells, and Plasma.--Livers  and spleens were 
removed aseptically from individual mice and homogenized in saline at 4°C with a motorized 
teflon pestle. 2 ml fractions of each homogenate were dispersed  by ultrasound and centrifuged 
lightly to remove gross debris.  Supernatants  were appropriately diluted in  MEM with 2% 
fetal calf serum for plaque assays and then stored for future use at --70°C. Feet were cut into 
eight pieces prior  to homogenization. 
Minimally heparinized blood was obtained from the retro-orbital plexus or from the heart, 
and  the cells  and plasma were separated.  Blood  ceils were washed twice in saline and  sus- 
pended in MEN[ with 2% fetal calf serum (20% v/v) for storage at -  70°C. Suspensions  were 
treated with ultrasound before performing plaque assays.  The total blood volume of a mouse 
in milliliters was assumed to be 10% of body weight in grams, 
Plasma was also stored at  --70°C and was treated with ultrasound at a  1:10 dilution in 
MEM with 2% fetal calf serum prior to determining its virus content. 
RESULTS 
Specificity  of A TS  In  Vitro.--The  immunosuppressive  activity  of  ATS  is 
thought  to  result  from its effects on thymus-derived  lymphocytes  (21).  How- 
ever,  before employing ATS  as  an  immunosuppressive  agent  for investigation 
of mechanisms  of recovery from mousepox,  it was  necessary  to  determine  its 
specificity,  since  reactivity  with  mouse  cells  other  than  lymphocytes  might 
significantly  influence  the  outcome  of  infection. 
Agglutination  using  C57BL  thymocytes,  peritoneal  cells,  and  RBC  with 
ATS, NRS,  and AMS  was  chosen  as  a  simple in vitro test;  cytotoxic activity 
was also present, but is not reported since it is unrelated to immunosuppressive 
potency  (22). 
On  morphological  criteria,  thymocyte  preparations  (pooled  from  3  normal 
mice)  used  in  these  tests  were  >99%  small  lymphocytes;  peritoneal  cells 
(pooled from 10 normal mice) were 37 %  large macrophages,  8 %  small lympho- 
cytes,  and  55 %  intermediate  cells,  i.e., medium  lymphocytes  or monocytes. 
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cytes, ATS gave higher titers than AMS; in the case of peritoneal cells, AMS 
gave higher titers than ATS, thus suggesting some degree of specificity of ATS 
for thymocytes. However, both ATS and AMS possessed RBC-agglutinating 
activity greater  than  that  for  either  of  the  nucleated  cell  types.  The  con- 
sequences of this activity in vivo will be described subsequently. 
It  is  important  to  note that  ATS  had  little  reactivity against  peritoneal 
cells, as previously noted by Mackaness and Hill (17). This suggested that very 
little anti-macrophage antibody was present, particularly since that proportion 
of the peritoneal cells which were of small and medium lymphocyte morphology 
could have accounted for the observed agglutination. Therefore, it was neces- 
TABLE I 
A gglutinin Titers of A TS, NRS, and A MS against Thymocytes, Peritoneal Cells, 
and Red Blood Cells 
Cell type  Serum  Reciprocal of titer 
Thymocytes 
Peritoneal cells 
Red blood ceils 
ATS  512 
NRS  8 
AMS  64 
ATS  32 
NRS  8 
AMS  256 
ATS  1024 
NRS  16 
AMS  512 
sary to determine if ATS contained antibodies with affinity for purified macro- 
phages. 
Various  dilutions  of AMS,  ATS,  and  NRS  were  incubated  with  purified 
cultures of C57BL mouse macrophages or thymocyte  smears, and rabbit gamma 
globulin  bound  to  the  cells was  then  detected by staining  with  fluorescein- 
conjugated goat  anti-(rabbit  globulin)  globulin. 
At a  1:8 dilution of the sera,  there was no evidence of macrophage-bound 
rabbit antibody with NRS; there was slight fluorescence with ATS and marked 
fluorescence with AMS  (Fig.  1).  With  thymocytes, ATS gave the most pro- 
nounced fluorescence, AMS gave slight fluorescence, and NRS none. 
These results confirmed those obtained by agglutination tests,  but in addi- 
tion revealed that ATS contained some antibody with affinity for macrophages. 
The effect of ATS  on macrophage function in vivo in relation to ectromelia 
virus will be described in a  later section. 
Ejects of A "IS on Blood Cell Counts In  Vivo.--Preliminary tests showed that 
ATS was  not  toxic for mice; 0.4 ml  could be injected intravenously without R.  V.  BLANDEN  1041 
FIG.  1.  Mouse  peritoneal  macrophages  stained  with  fluorescein-conjugated  anti-(rabbit 
globulin) globulin and counterstained with rhodamine bovine albumin following preincubation 
with  1:8 dilutions of NRS  (a),  ATS  (b),  or AMS  (c).  NRS-treated  cells exhibit slight, non- 
specific rhodamine fluorescence. Occasional ATS-treated cells show brighter, specific fluorescein 
emission, while most AMS-treated cells have strong, specific fluorescence. Fluorescence photo- 
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overt  ill effects  despite its  high  hemagglutinin  titer.  Thus  it was  decided to 
investigate the effects of ATS on the blood of mice rather than perform empirical 
absorption with mouse RBC. 
Groups of six C57BL  female mice 6  wk old were  injected with either ATS, 
NRS,  or  saline,  or  were  left  untreated.  The  regimen  consisted  of  two  sub- 
cutaneous injections of 0.2 ml 2  days apart. All mice were bled 3 hr after the 
second injection and blood cell counts were performed. 
The  effect of ATS  on  blood cell counts  is shown  in Table II. Total WBC 
counts in ATS-treated mice were less than half those of all control groups. This 
reduction was found to be highly significant when means were compared using 
the t  test.  On  the  other hand,  RBC  numbers  were not  significantly affected. 
TABLE II 
Blood Cell Counts* after A TS Treatment 
Small  Medium  Neutrophil 
and large  Monocytes  granulocytes  Treatment~t  RBC  Total WBC  lymphocytes  lymphocytes 
(X 10 6)  (X  10  3)  (X  10  2)  (X  10  3)  (X 10  '2)  (X  10~) 
ATS  7.9  -4-  1.9  2.5  +  0.5§  3.0  1.6  1.5  4.2 
NRS  7.5  4-  1.1  6.1  -4-  1.0  11.0  4.3  2.4  3.7 
Saline  7.4  ±  0.7  7.4  4-  2.2  15.5  5.0  3.0  5.2 
Nil  8.6  -4-  1.5  6.5  -4- 3.4  11.7  4.7  1.3  4.6 
* Counts expressed as ceils per cubic millimeter of blood.  Means of groups of six mice  ± 
standard deviations. 
2~ Two subcutaneous injections of 0.2 ml given 51 hr and 3 hr before bleeding. 
§ Significantly less than NRS (0.01  >  P  >  0.001),  saline (0.01 >  P  >  0.001),  and nil 
(0.05 >  P  >  0.02). 
Differential WBC  counts  allowed arithmetical  calculation  of  an  estimate  of 
the numbers of each morphological class of WBC  (the four right hand columns 
of Table n). This  revealed that  smaller numbers  of circulating lymphocytes 
accounted  for  the  total  WBC  depletion.  Further  examination  of  the  blood 
smears showed that there was no evidence of increased nmnbers of circulating 
normoblasts and reticulocytes in ATS-treated mice. Thus,  the possibility that 
large numbers of RBC had been removed from the circulation and replaced by 
immature  forms rapidly generated in hemopoietic tissue seemed unlikely. 
Effects  of A TS  on Organ  Weight  and Histopathology.--Organs  known  to be 
potentially important during infection were removed from groups of six mice 
48 hr after a  single subcutaneous dose of 0.2 ml ATS, or 3  and 48 hr after the 
second  of two  doses given 48  hr  apart.  Control mice  were  similarly treated 
with NRS  or saline, or left untreated. 
Livers, spleens, and thymuses were weighed and then fixed with 10 % formalin 
in saline together with popliteal lymph nodes. R.  V.  BLANDEN  1043 
Examination of hematoxylin- and eosin-stained sections revealed that ATS 
treatment caused a depletion of lymphocytes from the paracortical area of the 
popliteal lymph node and from the periarteriolar region of splenic lymphoid 
follicles. These effects were discernible after a single dose of ATS but were more 
pronounced after two doses. Liver and thymus were not affected histologically 
or  in weight  by ATS  treatment.  However, there was  an  increase  in  spleen 
weight 48 hr after the second dose of ATS  (69 ±  23 rag), NRS (60 4- 15 rag), 
or saline (59 4-  12 rag) which was significant (P <  0.05) when compared with 
untreated controls (40 4- 9 rag). 
The foregoing observations  on  the  effects of ATS  on  the blood ceils  and 
organs  of mice  are  essentially similar  to the more comprehensive studies  of 
Taub and Lance (23), with the exception that the present experiments showed 
no  depressive  effect of ATS  on  numbers  of  circulating  RBC  or  neutrophil 
granulocytes. 
Effects  of A TS on Macrophage Function in Vivo.--Since ATS contained slight 
but  detectable  anti-macrophage  activity  (Fig.  1)  and  since  its  anti-RBC 
activity may have promoted phagocytosis of RBC by fixed macrophages of the 
livers and  spleens  of ATS-treated mice,  functional changes  in  these  littoral 
phagocytes seemed possible  (24). During  natural mousepox, infection of the 
liver and spleen follows uptake of virus from the blood by these macrophages 
(12). Thus, events in vital target organs are critically dependent upon macro- 
phage function, and for this reason it was important to determine the fate of 
circulating  ectromelia virus  in  ATS-treated mice. 
Groups of 20 C57BL male mice 6 wk old were treated with either ATS or 
NRS (two subcutaneous injections of 0.2 ml 2 days apart)  and infected intra- 
venously with approximately 2 X  105 PFU Moscow strain ectromelia virus 3 
hr after the second ATS or NRS injection. Four mice of each group were bled 
from the retro-orbital plexus 5 rain after intravenous infection, and their livers 
and spleens were removed and snap frozen in liquid nitrogen within 7 rain of 
infection. Livers and spleens of further groups of four mice were taken after 4 
hr,  10 hr, 24 hr, and 48 hr. PFU in individual bloods and organs were deter- 
mined. 
The results are given in Table III. Over 99 % of virus had been cleared from 
the blood of both ATS- and NRS-treated mice 5 rain after intravenous injection. 
By 7 rain, less than 10% of injected virus could be located in the livers and 
spleens.  Since it has been demonstrated by Mires  (25)  that  the mouse liver 
takes up over 90%  of Moscow ectromelia virus within 5 mill of intravenous 
injection, at which time the virus is located within Kuppfer cells,  it is possible 
that  the failure to detect more virus in  this experiment was  due to a  rapid 
uncoating of virus within littoral macrophages. By 4 hr after injection, PFU 
numbers were beneath the technical limits of detection in both liver and spleen 
(at less than 0.1% of the injected dose). By 10 hr, virus was again detectable. 1044  EFFECTS  OF  ANTI-THYMOCYTE  SER'U~  ON  AfOUSEPOX 
At this time the fluorescence studies of Mims (26)  showed that  transmission 
of virus from infected liver macrophages  to  liver parenchyma cells could be 
first seen. Rapid multiplication of virus in both liver and spleen then occurred 
over the next 38 hr. Through all phases of infection, blood clearance, eclipse, 
and multiplication, there was no significanct difference (using t tests) between 
the levels of virus in the organs of ATS- and NRS-treated mice, thus indicating 
Distribution and Behavior of 
TABLE III 
Moscow Strain Ectromelia Virus* after Intravenous Injection o/ 
2 X  105 PFU 
Time after  Treatment:~  Blood  Liver  Spleen  infection 
5 min  ATS  2.5  4-  0.5 
NRS  2.5  4-  0.2 
7 min  ATS  --  4.1  +  0.2  1.8  4-  0.3 
NRS  --  4.0  -4- 0.1  1.5  4-  0.2 
4 hr  ATS  --  < 2.1  <0.70 
NRS  --  <2.1  <0.70 
10 hr  ATS  --  2.9  -4- 0.1  2.1  4-  0.2 
NRS  --  2.8  -4- 0.3  2.2  4-  0.2 
24 hr  ATS  --  5.9  -4- 0.3  4.8  4-  0.2 
NRS  --  6.3  -4- 0.3  5.2  4-  0.3 
48hr  ATS  --  8.3  4-  0.4  7.4  +  0.t 
NRS  --  8.1  -4- 0.2  7.3  4-  0.1 
* Expressed as mean log PFU per organ -4- standard deviations in groups of four mice. 
Two subcutaneous injections of 0.2 ml given 51 hr and 3 hr before injection of virus. 
that no important functional defect in the macrophages of the liver and spleen 
was caused by ATS treatment. 
Effect of A TS on the Course and Outcome of _Primary Mousepox.--Preliminary 
experiments showed  that even a single subcutaneous injection of 0.2 ml ATS 
caused over 80% of C57BL mice to die from a  subcutaneous infection with a 
dose  of  Moscow  strain  ectromelia virus  which  killed  none  of  the  controls 
treated with NRS or saline, or left untreated. The single injection of ATS could 
be given 2 days before, on the day of, or 2 days after infection. 
Fenner (12)  showed  that  subcutaneous infection in the  foot  resulted in a 
disease  indistinguishable from  natural mousepox,  and that  the  infected foot 
could be used conveniently  to quantitate infection at the portal of virus entry. 
Thus this route of infection was employed in the present experiment. R.  V.  BLANDEN  1045 
A group of 26 C57BL female mice 8 wk old was treated with two doses of 0.2 
ml of ATS given subcutaneously 2 days and 3 hr before infection. A  control 
group was similarly treated with NRS. All animals were infected subcutaneously 
in the right hind foot with 1@ PFU Moscow strain ectromelia virus. 10 mice of 
each group were set aside to assess  mortality, and 4 mice of each group were 
sacrificed 4, 6, and 7 days after infection. PFU in the infected foot, liver, spleen, 
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FIG. 2.  Cumulative mortality in ATS-treated and NRS-treated mice after subcutaneous 
infection with 103 PFU virulent, Moscow strain ectromelia virus. Two injections of 0.2 ml of 
ATS (or NRS) were given 51 hr and 3 hr before infection. 
neutralizing  antibody levels. Spleen homogenates of mice sacrificed on days 
4 and 6 were pooled and assayed for interferon. The spleen was chosen for this 
purpose because it is a major source of interferon during mousepox (11)  and 
provides a  relatively "clean" homogenate for processing. 
Cumulative mortality is  shown  in  Fig.  2  where  it  is  apparent  that  ATS 
treatment caused a highly significant increase in mortality (x  2 =  10.2, 0.01 > 
P  >  0.001). The probable explanation for this is revealed in Table IV which 
shows that the liver (a target organ vital for life), spleen, and blood of ATS- 
treated mice consistently contained more virus than NRS-treated controls on 
the 6th and 7th days after infection, although foot titers of both were similar. 
The virenaia  seemed to be  largely cell-associated as  reported previously by 
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The splenic interferon response is shown  in Table V. ATS-treated mice had 
higher levels than controls, possibly due to the larger stimulus of increased virus 
growth. However, no neutralizing antibody could be detected, even on the 7th 
day  (Table V)  and  too few  ATS-treated mice  survived  beyond this  time  to 
allow meaningful  comparison  with  controls.  Furthermore,  the  primary  foot 
infection precluded the footpad test for delayed hypersensitivity. Thus,  it was 
decided to  use  avirulent  Hampstead  egg  strain  virus  to  allow  ATS-treated 
mice to survive long enough for parallel studies of their delayed hypersensitivity 
and neutralizing antibody responses. 
TABLE IV 
Virus Content* of Tissues after Subcutaneous Infection with 10  3 PFU Moscow Strain Ectromdia 
Virus 
Day after  Treat- 








4.5  4-  0.3 
4.6  4- 0.7 
6.7  4-  0.8 
5.64-  0.8§ 
8.5  4-  1.7 
5.0  4-  2.8 
Spleen 
5.7  4- 0.5 
5.2  4-  1.4 
7.9  4-  0.2 
6.34-2.1 
8.94-  0.4 
5.4  4-  1.7§ 
Foot 
6.5  4- 0.2 
6.7  4-  0.1 
7.34-  0.2 
7.14-  0.2 
7.2  -4- 0.2 




2.6  ±  0.4 
4.8  4-  0.4 
3.4  4-  1.08 
5.6  4-  0.8 
3.6  4-  1.8 
Plasma 
2.34-  0.2 
2.24-  0.5 
4.2  4-  0.5 
3.04-1.1 
5.4  4-  0.9 
2.5  4-  1.5 
* Expressed as mean log PFU 4- standard deviations in groups of 4 mice. 
:~ Two subcutaneous  iniections of 0.2 ml given 51 hr and 3 hr before infection. 
§ Significantly  less than ATS group (P <  0.05). 
The Effects of A TS on the Delayed Hypersensitivity and Neutralizing Antibody 
Responses to  Ectromelia  Virus.--A  group  of 38  C57BL  female mice 8  wk old 
were treated with two doses of 0.2 inl ATS given subcutaneously over the left 
side of the thorax 2 days and 3 hr before infection. A  similar control group was 
treated with NRS.  23  mice of each group were  then  infected subcutaneously 
over the right side of the thorax with 5  X  105 PFU of Hampstead egg strain 
ectromelia virus. On days 5, 7, and 9 after infection, separate subgroups of five 
ATS- and five NRS-treated mice for each day were tested for delayed hyper- 
sensitivity. 
Five ATS-  and  five  NRS-treated  mice  which  had  not  been  infected were 
included in this test as controls indicating nonspecitic reactivity on each day. 
Since the  delayed hypersensitivity test  involved the injection of 106 PFU  of 
virulent Moscow strain ectromelia virus into the foot,  these  mice provided a 
concurrent test of the effect of ATS on mortality. R.  V.  BLANDEN  1047 
On days 8 and 10 after infection, separate subgroups of four ATS- and NRS- 
treated mice  were  bled for neutralizing  antibody assays.  These  times  were 
chosen on the basis of the preceding experiment and previous work by Schell 
(9) who showed that little or no antibody could be detected before the 8th day 
after infection with Hampstead egg strain ectromelia virus. Livers and spleens 
for PFU assays were taken from four mice of each group on days 6, 8, and 10 
after infection; on day 6, these organs were taken from mice used in delayed 
hypersensitivity tests,  and on days 8 and 10 from mice which had been bled 
for  antibody  assays. 
The delayed hypersensitivity and neutralizing antibody responses, and the 
virus content of organs, are shown in Table VI. The delayed hypersensitivity 
TABLE V 
Interferon  and  Neutralizing  Antibody  Responses  after  Subcutaneous  Infection  with  10 ~ PFU 
Moscow Strain Ectromelia  Virus 
Interferon  Neutralizing  Day after infection  Treatment*  (Units per spleen)~  antibody§ 
4  ATS  15  <5 
NRS  5  <5 
6  ATS  20  < 5 
NRS  S  <5 
7  ATS  --  <5 
NRS  --  <5 
* Subcutaneous injections of 0.2 ml given 51 hr and 3 hr before infection. 
:~ Derived from pools of four spleens. 
§ Reciprocal of titer. 
response (24 hr) was markedly depressed in ATS-treated mice so that it reached 
significant levels by day 9, 4 days later than in controls which gave good reac- 
tions when tested on day 5. On the other hand, immediate hypersensitivity (3 
hr) was not found in either ATS- or NRS-treated mice until day 9 when it was 
significantly  greater  in  NRS-treated  animals.  However,  virus-neutralizing 
activity of sera taken on days 8 and 10 was clearly unimpaired by ATS-treat- 
ment. 
The apparent discrepancy between the neutralizing antibody response and 
immediate  hypersensitivity,  which  is  also  presumably  antibody-mediated, 
could be due to the different test materials employed for measuring each re- 
sponse. Neutralization of virus depends upon interaction between antibody and 
accessible surface antigens of the infectious particle; a relatively pure prepara- 
tion of virions was found suitable for detecting this interaction and was rou- 
tinely employed in the assay. However, the material injected for hypersensitiv- 1048  EFFECTS  OF  ANTI--THYMOCYTE  SERUI~I  ON  I~OUSEPOX 
ity tests was a  crude homogenate of infected mouse spleens which contained 
both virions and other virus-specified antigenic products of infected cells, such 
as internal structural components of the virion or nonstructural proteins like 
the hemagglutinin  and various enzymes. It is  possible that  the virions com- 
prised a small proportion of the antigenic spectrum of the homogenate, so that 
they provided insufficient antigenic stimulus for an immediate hypersensitivity 
reaction. Alternatively, the class of antibody directed at virion surface antigens 
TABLE VI 
Neutralizing Antibody and Delayed Hypersensitivity Responses after Subcutaneous 
Infection with 5 X  105 PFU ttampstead  Egg Strain  Ectromelia Virus 
Day,'after  Treat-  PFU$  Neutralizing§  Hypersensitivity[[ 
infection  ment*  Liver  Spleen  antibody  3 hr  6  hr  24 hr 
5  ATS  --  --  --  0.2  4-  0.4  0  0 
NRS  --  --  --  0  0.2  4-  0.3  1.8  :::k 0.4¶ 
6  ATS  4.4  4-  0.5  6.0 4-  0.1  .... 
NRS  <2.4  1.2  4-  0.5  .... 
7  ATS  --  --  --  0.1  -4-  0.2  0  0.3  ::t:: 0.4 
NRS  --  --  --  0.3  4-  0.7  1.1  ::[:: 0.8¶  2.8  4-  1  2¶ 
8  ATS  3.2  4-  0.5  5.7  q-  0.6  25  4-  10  --  --  -- 
NRS  <2.4  <0.7  17.5  4-  5  --  --  -- 
9  ATS  --  --  --  1.3  ±  0.9  1.4 ::k  1.0  2.2  4-  1.0 
NRS  --  --  --  3.8  4-  1.5¶  4.4  4-  1.5¶  4.9  ::k  1.5¶ 
10  ATS  <2.4  4.0  4-  0.9  17.5  ±  5  --  --  -- 
NRS  <2.4  <0.7  22.5  -4-  13  --  --  -- 
* Two subcutaneous injections of 0.2 ml given 51 hr and 3 hr before infection. 
Mean log PFU 4- standard deviations in groups of four mice. 
§ Means of reciprocals of titers =i= standard deviations in groups of four mice. 
[I Means of increases in foot thickness (in 0.1 mm units)  4- standard deviations  in groups of five mice. The 24 
hr readings represent delayed hypersensitivity. 
¶  Significantly more than ATS groups (P <  0.05). 
which was detectable in 8  day sera may not be an efficient mediator of im- 
mediate hypersensitivity reactions. 
The nonspecific inflammatory response to the foot test injection in uninfected 
mice was similar in both ATS- and NRS-treated groups at all times, so that it 
iseems unlikely that anti-inflammatory qualities of tile ATS (27) contributed to 
the depression of the hypersensitivity reactions. Thus, the reduced reactivity 
probably  resulted  from  suppression  of  the  immune  response  to  ectromelia 
antigens. 
Virus grew far more in the livers and spleens of ATS-treated mice than in 
controls (Table VI). The failure to control virus growth was also reflected in 
mortality data from the mice acting as controls in the delayed hypersensitivity R.  V.  BLANDEN  1049 
test. 4  out of 15 NRS- and 14 out of 15 ATS-treated mice died. Thus, ATS 
again caused a highly significant increase in mortality (P <  0.001) even though 
the last ATS injections preceded infection by intervals of 5-9 days. 
DISCUSSION 
The ATS  used  in  these  experiments cross-reacted with  RBC  and macro- 
phages in vitro (Table I). However, this activity did not produce detectable 
side effects in vivo at dosages which dramatically increased susceptibility to 
mousepox.  Mice  could  tolerate  large  intravenous  injections  of  ATS;  sub- 
cutaneous inoculation caused depletion of lymphocytes from thymus-depend- 
ent  areas  (23)  of the popliteal lymph node and spleen, and reduced the num- 
bers of circulating lymphocytes without affecting other cell types in the blood 
(Table II). Most importantly, the clearance of ectromelia virus from the blood, 
and its subsequent distribution and behavior in the liver and spleen over a 48 
hr time period was not influenced by ATS treatment (Table III). Thus, since 
the  innate  resistance  of these  important target  organs was  not  altered,  the 
effects of ATS on the course and outcome of infection could be attributed to 
depression of acquired mechanisms  of recovery. 
The early studies of  Fenner  (12)  on  the  pathogenesis  of  mousepox  using 
virulent virus  in susceptible outbred mice showed that  the natural  route of 
infection was through skin abrasions. After local multiplication in the skin and 
in draining lymph nodes, there was a primary viremia. By 3 days, infection of 
the liver and spleen was detectable, presumably as a consequence of uptake of 
blood-borne  virus  by  littoral  macrophages,  as  later  shown  by  Mims  (25). 
Rapid multiplication of virus then occurred in these organs and probably con- 
tributed to a secondary viremia which in turn led to extensive focal infection 
of the skin. If the mouse survived beyond 7 or 8 days after infection, a  rash 
developed at these skin loci and then healed within a few more days. Deaths 
could be attributed to unchecked growth of virus and massive necrosis in the 
liver (28). However, in survivors the rate of growth of virus in the spleen began 
to decrease by the 6th day of infection (10) which suggested the onset of re- 
covery mechanisms  by this  time.  In  contrast,  virus growth  in  the  foot, the 
portal of entry in these experiments, did not slow for another 4 days (10). 
The current  investigation using  both virulent  and  avirulent virus  strains 
and more resistant  C57BL mice has  confirmed and extended these findings. 
Since ATS treatment caused a highly significant increase in mortality rate in 
mice  infected subcutaneously with  virulent Moscow strain  ectromelia virus 
(Fig.  2),  it provided a  means  of determining the  time  of onset of recovery 
mechanisms. For example, ATS-treated mice began to die 6 days after infec- 
tion, indicating that NRS-treated controls (most of which survived) must have 
generated  effective recovery mechanisms  before  this  time.  This  is  further 
illustrated by the fact that more virus was found in the livers, spleens,  and 1050  EFFECTS  OF  ANTI--THYMOCYTE  SERUM  ON  MOUSEPOX 
blood of ATS-treated mice on the 6th and 7th days after infection than in the 
organs of controls (Table IV). Since organ levels on the 4th day were similar, 
it follows that  the innate resistance of the mouse was not changed by ATS, 
and  that  acquired  recovery mechanisms  began  to  operate  between 4  and  6 
days after infection. Table IV also shows that these mechanisms did not control 
virus in  the foot as  effectively as  in the spleen  and liver,  perhaps  reflecting 
relative inaccessability of virus located in foot tissues. 
We can now question the nature of the defect in recovery mechanisms caused 
by ATS.  The  host  responses measured  in  the  present  experiments may be 
evaluated in terms of their presence or absence at the time of onset of recovery, 
and their susceptibility to impairment by ATS. Table V shows that the splenic 
interferon response,  although present at times relevant to recovery, was cer- 
tainly not depressed by ATS. Thus, it appears unlikely that interferon plays a 
major role in  recovery. 
There  was  also  no  impairment  of  the  neutralizing  antibody  response  of 
ATS-treated mice to avirulent Hampstead egg strain virus (Table VI) although 
their  recovery  mechanisms  were  unequivocally  defective  as  indicated  by 
increased  multiplication  of  avirulent  virus  in  target  organs  and  increased 
mortality  after  infection with  virulent  virus.  Furthermore,  no  neutralizing 
antibody had appeared in circulation by late on the 7th day after infection with 
virulent virus; that is  at least 2 days later than the onset of recovery in the 
spleen  and  liver  (Table V).  Similarly,  immediate  hypersensitivity to  ectro- 
melia antigens  (Table VI), which is also presumably antibody-mediated, was 
not at significant levels 7 days after infection with avirulent virus, although 
ATS did cause a significant depression in the levels of reactivity 9 days after 
infection. Superficially, these results are strong evidence against an important 
role for antibodies in recovery. However, it is possible that during mousepox 
infection, antibody is being produced in lymphoid tissues several days before it 
is  detectable in  the  circulation. The absence of circulating antibodies  in  the 
early stages of infection might then be explained by their rapid absorption by 
excess viral antigens in infected tissues  (29, 30). This also implies that excess 
free virus would remain available to promote further spread of infection, but 
it is  conceivable that  antibody could make some contribution to the control 
of infection before becoming detectable in the blood. The magnitude  of this 
contribution cannot be accurately assessed in the present experiments, although 
the fact that excessive growth  of virus occurred in ATS-treated mice in  the 
face of what appears to be a normal neutralizing antibody response (Table VI) 
makes  it  seem  improbable  that  antibody  is  a  key factor in  recovery. This 
question will be examined more closely in a future paper. 
In contrast to its failure to affect interferon or neutralizing antibody produc- 
tion, ATS caused a significant delay in the cell-mediated immune response so 
that ATS-treated mice took 9 days to generate a level of delayed hypersensitiv- R.  V.  BLANDEN  1051 
ity to ectromelia virus antigens  already present by 5 to 7 days in NRS-treated 
animals (Table VI). This is in keeping with other evidence which indicates that 
ATS  may selectively  depress  thymus-dependent immune  responses (which 
include  cell-mediated  immunities and humoral  antibody responses to certain 
antigens  in some animal species) while leaving thymus-independent antibody 
responses intact (4, 21, 31). Furthermore, cell-mediated immunity was detect- 
able  at a  time compatible  with a  role  in  recovery.  The  significant  delayed 
hypersensitivity reaction following a  test injection on  day 5  after infection 
indicated the availability of significant numbers of specifically reactive lym- 
phocytes at this time. There is now considerable evidence from other experi- 
mental systems which shows that the cell-mediated  response in mousepox is 
not uniquely early. The studies of Turk (32) on the cytodynamics of delayed 
hypersensitivity responses to skin sensitizing agents suggested that specifically 
reactive  small  lymphocytes were  generated  in  responding  lymph nodes  of 
guinea pigs by the 5th day after antigen administration. Furthermore, Allison 
has obtained delayed hypersensitivity reactions to  rabbitpox (7) and  fibroma 
viruses  (5, 6)  in rabbits 4 or 5 days after infection,  while delayed hypersen- 
sitivity to some bacterial antigens  and associated  acquired  resistance  mech- 
anisms are well established  in mice within 4 days (33). 
The foregoing evidence, which suggests the potential importance of a thymus- 
dependent response in recovery from mousepox, is in accord with the finding of 
Subrahmanyan (34) that neonatal thylnectomy  resulted in increased mortality 
of  susceptible  outbred mice  after  infection  with  avirulent Hampstead  egg 
strain ectromelia virus. However,  Subrahlnanyan also showed that this effect 
could be abrogated by feeding the mice antibiotics from birth, and that mortal- 
ity of thymectomized mice from a low pathogen colony was unaltered. This 
suggested  a  complex  interaction  between  the  thymus-dependent  immune 
system, bacterial flora, and the virus which remains unexplained. 
Thus, the available evidence would support the contention that cell-mediated 
immunity plays an essential  role in recovery  from mousepox,  and that the 
interferon and antibody responses are of secondary importance.  Similar conclu- 
sions have been drawn from studies with other poxivruses (3, 5, 6) as detailed 
in the introduction of this paper. 
Future articles will present evidence derived from a positive approach  to the 
problem  of  recovery  from mousepox  employing  transfer  of  immune spleen 
cells, immune serum, and interferon to preinfected recipients, and also evidence 
concerning the possible nature of antiviral mechanisms generated by the cell- 
mediated immune response. 
SUMMARY 
Agglutination and immunofluorescence tests in vitro showed that the ATS 
used in these experiments cross-reacted with macrophages and RBC. However, 1052  EFEECTS  OF  ANTI-THYMOCYTE  SERUM  ON  MOUSEPOX 
ATS  was  not  toxic  in  vivo,  and  small  doses  given  subcutaneously  depleted 
thymus-dependent  areas  of lymphoid tissues  and  selectively depressed  blood 
lymphocyte counts without affecting other cell types in the blood. Furthermore, 
the  function  of littoral  macrophages  as  indicated  by the  clearance  of blood- 
borne virus  and  its  subsequent  behavior over a  48 hr period  in the liver  and 
spleen  was  not  changed  by ATS.  Thus,  the  innate  resistance  of  these  vital 
target organs was not depressed. A similar regimen of subcutaneous ATS caused 
a  highly significant  increase  in  mortality  from mousepox with  an  associated 
failure to control virus growth in the liver and spleen which was manifest by 6 
days after infection. The interferon  and neutralizing  antibody responses were 
not  impaired  in  ATS-treated  mice,  but  the  cell-mediated  immune  response 
was  significantly  suppressed.  This  evidence,  and  consideration  of the  timing 
of these host responses during the course of infection in relation to the control 
of virus growth in the liver and spleen, led to the conclusion that cell-mediated 
immunity  probably  contributed  an  essential  acquired  recovery  mechanism. 
However,  no  evidence  was  obtained  concerning  the  nature  of  this  antiviral 
mechanism. 
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